On June 16, 2020, Generation Bio, an innovative genetic medicines company creating a new class of gene therapy, announced the closing of its initial public offering. The company sold 12,105,263 shares of its common stock at a public offering price of $19.00 per share, reflecting the full exercise of the underwriters’ option to purchase additional shares, for aggregate gross proceeds of approximately $230 million, before deducting underwriting discounts and commissions and estimated offering expenses. The shares are listed on the Nasdaq Global Select Market (GBIO). J.P. Morgan Securities LLC, Jefferies LLC and Cowen and Company LLC acted as joint book running managers and Wedbush PacGrow acted as lead manager of the offering.

The deal team representing Generation Bio was led by Stuart Falber and Molly Fox.